Ezio Bonvini's most recent trade in Macrogenics Inc was a trade of 187,500 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 187,500 | 187,500 | - | - | Employee Stock Option (right to buy) | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 31,250 | 31,250 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 16,665 | 0 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 16,665 | 152,232 (0%) | 0% | - | Common Stock | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.71 per share. | 12 Feb 2026 | 6,433 | 145,799 (0%) | 0% | 1.7 | 11,000 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2026 | 11,166 | 139,878 (0%) | 0% | - | Common Stock | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2026 | 11,166 | 11,166 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2026 | 7,001 | 131,415 (0%) | 0% | - | Common Stock | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2026 | 7,001 | 13,999 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.81 per share. | 07 Feb 2026 | 4,311 | 135,567 (0%) | 0% | 1.8 | 7,803 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.81 per share. | 07 Feb 2026 | 2,703 | 128,712 (0%) | 0% | 1.8 | 4,892 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 16,665 | 16,665 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 16,665 | 124,414 (0%) | 0% | 0 | Common Stock | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 128,000 | 128,000 | - | - | Employee Stock Option (right to buy) | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 21,000 | 21,000 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 11,168 | 112,060 (0%) | 0% | - | Common Stock | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 11,168 | 22,332 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.60 per share. | 07 Feb 2025 | 4,311 | 107,749 (0%) | 0% | 2.6 | 11,209 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 28,125 | 0 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2024 | 28,125 | 110,258 (0%) | 0% | 0 | Common Stock | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.11 per share. | 22 Feb 2024 | 9,366 | 100,892 (0%) | 0% | 17.1 | 160,252 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 16,670 | 88,004 (0%) | 0% | 0 | Common Stock | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 16,670 | 33,330 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.40 per share. | 15 Feb 2024 | 5,871 | 82,133 (0%) | 0% | 17.4 | 102,155 | Common Stock |
| Macrogenics Inc | Bonvini Ezio | Sr VP, Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 90,000 | 90,000 | - | - | Employee Stock Option (right to buy) | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 33,500 | 33,500 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 07 Feb 2024 | 3,334 | 71,334 (0%) | 0% | 18 | 60,012 | Common Stock |
| Macrogenics Inc | Bonvini Ezio | Sr VP, Research & CSO | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 01 Feb 2024 | 13,316 | 74,668 (0%) | 0% | 15 | 199,740 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 19 Jan 2024 | 13,316 | 87,984 (0%) | 0% | 12 | 159,792 | Common Stock |
| Macrogenics Inc | Bonvini Ezio | Sr VP, Research & CSO | Sale of securities on an exchange or to another person at price $ 10.08 per share. | 20 Dec 2023 | 18,880 | 101,300 (0%) | 0% | 10.1 | 190,310 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2023 | 9,375 | 0 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2023 | 9,375 | 123,799 (0%) | 0% | 0 | Common Stock | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.55 per share. | 22 Feb 2023 | 3,619 | 120,180 (0%) | 0% | 6.5 | 23,704 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 200,000 | 200,000 | - | - | Employee stock option (right to buy) | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 50,000 | 50,000 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2022 | 5,000 | 0 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2022 | 5,000 | 116,090 (0%) | 0% | 0 | Common Stock | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.16 per share. | 14 May 2022 | 1,666 | 114,424 (0%) | 0% | 4.2 | 6,931 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 75,000 | 75,000 | - | - | Employee stock option (right to buy) | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 37,500 | 37,500 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 16 Nov 2021 | 2,540 | 111,090 (0%) | 0% | 16 | 40,640 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2021 | 2,540 | 0 | - | - | Employee stock option (right to buy) | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2021 | 21,855 | 2,540 | - | - | Employee stock option (right to buy) | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 24 Jun 2021 | 21,855 | 104,329 (0%) | 0% | 16 | 349,680 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.53 per share. | 24 Jun 2021 | 4,221 | 108,550 (0%) | 0% | 20.5 | 86,657 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2021 | 4,221 | 63,279 | - | - | Employee stock option (right to buy) | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2021 | 5,000 | 5,000 | - | - | Restricted Stock Unit | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2021 | 5,000 | 84,890 (0%) | 0% | - | Common Stock | |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.49 per share. | 14 May 2021 | 2,416 | 82,474 (0%) | 0% | 29.5 | 71,248 | Common Stock |
| Macrogenics Inc | Ezio Bonvini | Sr VP, Research & CSO | Sale of securities on an exchange or to another person at price $ 32.00 per share. | 22 Mar 2021 | 3,917 | 79,890 (0%) | 0% | 32 | 125,344 | Common Stock |